Live progression free from multiple myeloma longer.

For adults with Multiple Myeloma who have received at least 2 prior treatments

Going progression free longer means going longer without your Multiple Myeloma getting worse

In a clinical study, SARCLISA given with Pomalyst® (pomalidomide) and dexamethasone (Pd) extended the time people lived without their multiple myeloma getting worse compared to Pd alone (median of 11.5 months vs 6.5 months).

SARCLISA trial results

SARCLISA was
proven in a Phase 3 study.

See the Results

Target icon

SARCLISA is a targeted
immunotherapy that works
together with your
immune system.

See How It Works

Quiz icon

Answer 7 short questions
to find out if SARCLISA
could be appropriate for you.

Take a Short Quiz